Sam Brusco, Associate Editor11.22.22
QIAGEN has launched a monkeypox (MPXV) test for its NeuMoDx automated PCR platform to boost surveillance and research into the current outbreak in non-endemic regions.
The NeuMoDx Test Strip is currently for research use only (RUO). The multiplex test identifies both monkeypox variants. The dual-target assay aims to reduce false negative results that incorrectly indicate viral absence. It distinguishes between the clade I and clade II variants, delivering results in about 70 minutes on QIAGEN’s NeuMoDx 96 and 288 molecular systems.
“NeuMoDx MPXV enables researchers the fast and reliable qualitative detection and differentiation of both monkeypox clades, a huge help for those trying to understand and contain this virus,” Jean-Pascal Viola, senior Vice VP, head of the molecular diagnostics business at QIAGEN, told the press.
The assay extract DNS from lesion fluid swabs to isolate targeted nucleic acids and then conducts a real-time PCR. Test strips and core reagents and consumables are ready-to-use, can remain on board for a minimum of seven days, and can be loaded while the system is operating. The system can run up to 30 different assays and offers the versatility to run IVD certified assays, self-developed tests (SDTs), and RUO assays.
Some 78,000 people in more than 110 countries have been infected with the virus since the latest outbreak began this spring, according to the World Health Organization (WHO).
The NeuMoDx Test Strip is currently for research use only (RUO). The multiplex test identifies both monkeypox variants. The dual-target assay aims to reduce false negative results that incorrectly indicate viral absence. It distinguishes between the clade I and clade II variants, delivering results in about 70 minutes on QIAGEN’s NeuMoDx 96 and 288 molecular systems.
“NeuMoDx MPXV enables researchers the fast and reliable qualitative detection and differentiation of both monkeypox clades, a huge help for those trying to understand and contain this virus,” Jean-Pascal Viola, senior Vice VP, head of the molecular diagnostics business at QIAGEN, told the press.
The assay extract DNS from lesion fluid swabs to isolate targeted nucleic acids and then conducts a real-time PCR. Test strips and core reagents and consumables are ready-to-use, can remain on board for a minimum of seven days, and can be loaded while the system is operating. The system can run up to 30 different assays and offers the versatility to run IVD certified assays, self-developed tests (SDTs), and RUO assays.
Some 78,000 people in more than 110 countries have been infected with the virus since the latest outbreak began this spring, according to the World Health Organization (WHO).